TORONTO, Dec. 16, 2020 /CNW/ - VIVO Cannabis
Inc. (TSX: VIVO) (OTCQX: VVCIF) ("VIVO" or the
"Company") is pleased to provide an update on its medical
cannabis business.
Medical cannabis patients with authorizations in Canada can now purchase a variety of Canna
Farms™ craft premium dried flower and pre-roll strains and
solventless concentrates through the Medical Cannabis by Shoppers™
online sales platform. Canna Farms™ Kief and Bubble Hash products
are the first in their concentrate categories to launch with
Medical Cannabis by Shoppers™ and offer experienced patients
the option of higher potency, quicker onset of action delivery
formats.
"We're proud to offer our quality-tested products through a
trusted pharmacy network which is helping to shape the medical
cannabis community," said Barry
Fishman, Chief Executive Officer of VIVO. "We have
aligned visions for product standardization and consistency for
medical cannabis patients, and we look forward to further
collaboration with Medical Cannabis by Shoppers Drug Mart
Inc. and the introduction of additional novel products."
VIVO also announced that a selection of its Canna Farms™ and
Beacon Medical™ products will be available to patients in the
previously announced University Health Networks' ("UHN") Medical
Cannabis Real-World Evidence Study, in partnership with Medical
Cannabis by Shoppers Drug Mart Inc.
Led by UHN's Dr. Hance Clark, the first-of-its-kind,
prospective, non-interventional, observational study that will
involve a nation-wide clinical trial to examine the impact of
medical cannabis on sleep, pain, anxiety and depression issues. The
study will enroll about 2,000 patients who will be followed over a
24-week period to determine the efficacy of medical cannabis on
producing positive health outcomes.
As part of the study, all Canna Farms™ and Beacon Medical™
products will undergo additional testing, with results registered
on TruTrace Technologies software platform that is integrated
through the Medical Cannabis by Shoppers online platform and
will capture detailed data about each product for patients in the
clinical trial. VIVO products starting in the new year.
"We are excited to participate in this groundbreaking study in
partnership with UHN and Medical Cannabis by Shoppers Drug Mart
Inc.," said Carole Chan, Chief
Commercial Officer of VIVO. "At VIVO, we are uniquely committed to
our medical business and are supportive of this concerted effort to
bring greater clarity and consistency to the medical cannabis
space, by elevating the standards of quality control."
About VIVO Cannabis™
VIVO Cannabis™ is recognized for trusted, premium cannabis
products and services. It holds production and sales licences from
Health Canada and operates world-class indoor and seasonal airhouse
cultivation facilities. VIVO has a collection of premium brands,
each targeting different customer segments, including Canna Farms™,
Beacon Medical™, Fireside™, Fireside-X™, Lumina™ and Canadian
Bud Collection™. Harvest Medicine,
VIVO's patient-centric, scalable network of medical cannabis
clinics, has serviced over 150,000 patient visits. VIVO is pursuing
several partnership and product development opportunities and is
focusing its international efforts on Germany and Australia. For more information visit:
vivocannabis.com
Disclaimer for Forward-Looking Information
Certain statements in this news release are forward-looking
statements, which are statements that are not purely historical,
including statements regarding the beliefs, plans, expectations or
intentions of VIVO and its management regarding the future.
Forward-looking statements in this news release include statements
regarding: that the Company's activities to date are expected to
help solidify its market presence in the medical cannabis space;
and factors that VIVO believes will drive significant growth in
medical cannabis utilization.
Such statements are subject to risks and uncertainties that
may cause actual results, performance or developments to differ
materially from those contained in the forward-looking statements,
including: that the medical cannabis market may not grow to the
extent, within the time, or for the reasons expected by the
Company; that the COVID-19 pandemic may last longer and have a more
significant impact on the Company's operations, the Canadian
cannabis industry, or the global economy generally, than currently
expected; that the Company may not be able to launch new products
in the time expected or at all and that patients may not receive
the expected benefits therefrom; that the Company may not be able
to achieve competitive margins; that new products, if launched, may
not be accepted by the market or may become subject to product
liability claims; that the Company may not be able to obtain
necessary licences ; and other factors beyond the Company's
control.
No assurance can be given that any of the events anticipated
by the forward-looking statements will occur or, if they do occur,
what benefits the Company will obtain from them. Readers are urged
to consider these factors, and the more extensive risk factors
included in the Company's management's discussion and analysis for
the three months ended September 30,
2020, which is available on SEDAR, carefully in evaluating
the forward-looking statements contained in this news release, and
are cautioned not to place undue reliance on such forward-looking
statements, which are qualified in their entirety by these
cautionary statements. The forward-looking statements in this news
release are made as of the date hereof and the Company disclaims
any intent or obligation to update publicly any such
forward-looking statements, whether as a result of new information,
future events or results or otherwise, except as required by
applicable securities laws.
SOURCE VIVO Cannabis Inc.